This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20https://kar.kent.ac.uk/77398/
dctermshttp://purl.org/dc/terms/
n2https://kar.kent.ac.uk/id/eprint/
n14https://kar.kent.ac.uk/id/eprint/77398#
n11doi:10.1038/
wdrshttp://www.w3.org/2007/05/powder-s#
n13http://purl.org/ontology/bibo/status/
dchttp://purl.org/dc/elements/1.1/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n17https://demo.openlinksw.com/about/id/entity/https/raw.githubusercontent.com/annajordanous/CO644Files/main/
n18http://eprints.org/ontology/
bibohttp://purl.org/ontology/bibo/
n9https://kar.kent.ac.uk/id/publication/
n12https://kar.kent.ac.uk/id/org/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4https://kar.kent.ac.uk/id/
n6https://kar.kent.ac.uk/id/document/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16https://demo.openlinksw.com/about/id/entity/https/www.cs.kent.ac.uk/people/staff/akj22/materials/CO644/
n7https://kar.kent.ac.uk/id/person/

Statements

Subject Item
n2:77398
rdf:type
bibo:Article n18:ArticleEPrint bibo:AcademicArticle n18:EPrint
rdfs:seeAlso
n20:
owl:sameAs
n11:bjc.2017.387
n18:hasAccepted
n6:3190358
n18:hasDocument
n6:3190364 n6:3190358 n6:3190394 n6:3190391 n6:3190392 n6:3190393
dc:hasVersion
n6:3190358
dcterms:title
MYC regulation of glutamine--proline regulatory axis is key in luminal B breast cancer
wdrs:describedby
n16:export_kar_RDFN3.n3 n17:export_kar_RDFN3.n3
dcterms:date
2018-01-23
dcterms:creator
n7:ext-0267438d637496e3c5a459736527b4c5 n7:ext-115a5b0d59495480e26b24443fb44ed9 n7:ext-0496b2bbc4adb5af49e256ac95d0b0d2 n7:ext-55920ac763ad524ab08d4c124ffb4875 n7:ext-dddb21b1afc3cd07c34fdc4d19159d58 n7:ext-283b0f48cd1c70d5e7d9aaa2688606ad n7:ext-288425ca2efb9fb8d1eb3969958cdc47 n7:ext-8235d4dc25a7f59f521f7284ff323038 n7:ext-20192a6facfa167903e5c83ed8b45aee n7:ext-63ac3493c5f26bf67603e297d39334f9 n7:ext-3b40414b3b9cbe92568f7d76a1770a03 n7:ext-d.soria@kent.ac.uk n7:ext-e40dc876ab5ac330e6471815b34c894d
bibo:status
n13:peerReviewed n13:published
dcterms:publisher
n12:ext-5e5a54cc3e497cc2c4751d0ad0d5c369
bibo:abstract
Background: Altered cellular metabolism is a hallmark of cancer and some are reliant on glutamine for sustained proliferation and survival. We hypothesise that the glutamine–proline regulatory axis has a key role in breast cancer (BC) in the highly proliferative classes. Methods: Glutaminase (GLS), pyrroline-5-carboxylate synthetase (ALDH18A1), and pyrroline-5-carboxylate reductase 1 (PYCR1) were assessed at DNA/mRNA/protein levels in large, well-characterised cohorts. Results: Gain of PYCR1 copy number and high PYCR1 mRNA was associated with Luminal B tumours. High ALDH18A1 and high GLS protein expression was observed in the oestrogen receptor (ER)+/human epidermal growth factor receptor (HER2)– high proliferation class (Luminal B) compared with ER+/HER2– low proliferation class (Luminal A) (P=0.030 and P=0.022 respectively), however this was not observed with mRNA. Cluster analysis of the glutamine–proline regulatory axis genes revealed significant associations with molecular subtypes of BC and patient outcome independent of standard clinicopathological parameters (P=0.012). High protein expression of the glutamine–proline enzymes were all associated with high MYC protein in Luminal B tumours only (P<0.001). Conclusions: We provide comprehensive clinical data indicating that the glutamine–proline regulatory axis plays an important role in the aggressive subclass of luminal BC and is therefore a potential therapeutic target.
dcterms:isPartOf
n4:repository n9:ext-00070920
bibo:authorList
n14:authors
bibo:issue
2
bibo:volume
118